{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:09:31Z","timestamp":1793506171959,"version":"4.5.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Uveal melanoma (UM) is one of the most prevalent types of intraocular melanomas, which has relatively high morbidity and mortality rates despite being a rare disease. Genetic modifications are one of the prime driving forces behind cellular growth, proliferation, and migration in UM, among which mutation of driver genes (e.g., GNA11, GNAQ, BAP1, EIF1AX, and SF3B1, etc.) and epigenetic modifications (e.g., DNA methylation, histone modifications, and non-coding RNAs) are the key drivers behind oncogenesis. A feasible treatment approach for UM could be gene therapy targeting these genetic mutations and implicated pathways. In this review, current therapeutic options for the treatment of primary and metastatic UM will be briefly discussed in the context of the major driver gene and epigenetic mutations in UM. Primary focus will be on the current state of RNA interference, non-coding RNA, gene editing, gene replacement, and suicide gene therapies for UM, including prospective targeting strategies.<\/jats:p>","DOI":"10.1007\/s12094-026-04499-y","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T07:46:00Z","timestamp":1784015160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Gene therapy for uveal melanoma"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-4158","authenticated-orcid":false,"given":"Anika","family":"Bushra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0630-1520","authenticated-orcid":false,"given":"Joseph","family":"Irudayaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"4499_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-024-00182-2","author":"YZ Beigi","year":"2024","unstructured":"Beigi YZ, Lanjanian H, Fayazi R, Salimi M, Hoseyni BHM, Noroozizadeh MH, et al. Heterogeneity and molecular landscape of melanoma: implications for targeted therapy. Mol Biomed. 2024. https:\/\/doi.org\/10.1186\/s43556-024-00182-2.","journal-title":"Mol Biomed"},{"key":"4499_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102599","volume":"119","author":"M Wespiser","year":"2023","unstructured":"Wespiser M, Neidhardt E, Negrier S. Uveal melanoma: in the era of new treatments. Cancer Treat Rev. 2023;119:102599. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102599.","journal-title":"Cancer Treat Rev"},{"key":"4499_CR3","doi-asserted-by":"publisher","DOI":"10.1177\/1758834018757175","author":"J Yang","year":"2018","unstructured":"Yang J, Manson DK, Marr BP, Carvajal RD. Treatment of uveal melanoma: where are we now? Ther Adv Med Oncol. 2018. https:\/\/doi.org\/10.1177\/1758834018757175.","journal-title":"Ther Adv Med Oncol"},{"key":"4499_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26199799","volume":"26","author":"L Iavarone","year":"2025","unstructured":"Iavarone L, Franco R, Zito Marino F, D\u2019Abbronzo G, Argenziano G, Scharf C, et al. Ocular melanoma: a comprehensive review with a focus on molecular biology. Int J Mol Sci. 2025;26:9799. https:\/\/doi.org\/10.3390\/ijms26199799.","journal-title":"Int J Mol Sci"},{"key":"4499_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16142510","volume":"16","author":"D Lamas-Francis","year":"2024","unstructured":"Lamas-Francis D, Rodr\u00edguez-Fern\u00e1ndez CA, de Esteban-Maci\u00f1eira E, Silva-Rodr\u00edguez P, Pardo M, Bande-Rodr\u00edguez M, et al. Impact of driver mutations on metastasis-free survival in uveal melanoma: a meta-analysis. Cancers (Basel). 2024;16:2510. https:\/\/doi.org\/10.3390\/cancers16142510.","journal-title":"Cancers (Basel)"},{"key":"4499_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-66428-x","author":"JJ Dollar","year":"2025","unstructured":"Dollar JJ, Decatur CL, Weis E, Schefler AC, Materin MA, Fuller TS, et al. Early genetic evolution of driver mutations in uveal melanoma. Nat Commun. 2025. https:\/\/doi.org\/10.1038\/s41467-025-66428-x.","journal-title":"Nat Commun"},{"key":"4499_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133147","volume":"14","author":"M Solnik","year":"2022","unstructured":"Solnik M, Paduszy\u0144ska N, Czarnecka AM, Synoradzki KJ, Yousef YA, Chor\u0105giewicz T, et al. Imaging of uveal melanoma\u2014current standard and methods in development. Cancers (Basel). 2022;14:3147. https:\/\/doi.org\/10.3390\/cancers14133147.","journal-title":"Cancers (Basel)"},{"key":"4499_CR8","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s11912-025-01684-0","volume":"27","author":"DC Ziogas","year":"2025","unstructured":"Ziogas DC, Foteinou D, Theocharopoulos C, Martinos A, Petsiou DP, Anastasopoulou A, et al. State-of-the-art in metastatic uveal melanoma treatment: a 2025 update. Curr Oncol Rep. 2025;27:803\u201321. https:\/\/doi.org\/10.1007\/s11912-025-01684-0.","journal-title":"Curr Oncol Rep"},{"key":"4499_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0158-0","author":"MJ Jager","year":"2020","unstructured":"Jager MJ, Shields CL, Cebulla CM, Abdel-Rahman MH, Grossniklaus HE, Stern MH, et al. Uveal melanoma. Nat Rev Dis Primers. 2020. https:\/\/doi.org\/10.1038\/s41572-020-0158-0.","journal-title":"Nat Rev Dis Primers"},{"key":"4499_CR10","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2021.10863","author":"D Branisteanu","year":"2021","unstructured":"Branisteanu D, Bogdanici C, Branisteanu D, Maranduca M, Zemba M, Balta F, et al. Uveal melanoma diagnosis and current treatment options (review). Exp Ther Med. 2021. https:\/\/doi.org\/10.3892\/etm.2021.10863.","journal-title":"Exp Ther Med"},{"key":"4499_CR11","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/ceo.14214","volume":"51","author":"H Bai","year":"2023","unstructured":"Bai H, Bosch JJ, Heindl LM. Current management of uveal melanoma: a review. Clin Exp Ophthalmol. 2023;51:484\u201394. https:\/\/doi.org\/10.1111\/ceo.14214.","journal-title":"Clin Exp Ophthalmol"},{"key":"4499_CR12","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1038\/s41433-024-03035-y","volume":"38","author":"YH Tseng","year":"2024","unstructured":"Tseng YH, Hsu CA, Chou YB. Comparing efficacy of charged-particle therapy with brachytherapy in treatment of uveal melanoma. Eye. 2024;38:1882\u201390. https:\/\/doi.org\/10.1038\/s41433-024-03035-y.","journal-title":"Eye"},{"key":"4499_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16203497","volume":"16","author":"AW Chan","year":"2024","unstructured":"Chan AW, Lin H, Yacoub I, Chhabra AM, Choi JI, Simone CB 2nd. Proton therapy in uveal melanoma. Cancers (Basel). 2024;16:3497. https:\/\/doi.org\/10.3390\/cancers16203497.","journal-title":"Cancers (Basel)"},{"key":"4499_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020333","volume":"15","author":"M Zemba","year":"2023","unstructured":"Zemba M, Dumitrescu OM, Gheorghe AG, Radu M, Ionescu MA, Vatafu A, et al. Ocular complications of radiotherapy in uveal melanoma. Cancers (Basel). 2023;15:333. https:\/\/doi.org\/10.3390\/cancers15020333.","journal-title":"Cancers (Basel)"},{"key":"4499_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/etm.2020.9344","volume":"20","author":"S S\u0103ftescu","year":"2020","unstructured":"S\u0103ftescu S, Popovici D, Oprean C, Negru A, Croitoru A, Zemba M, et al. Endurance of erythrocyte series in chemotherapy. Exp Ther Med. 2020;20:1\u20131. https:\/\/doi.org\/10.3892\/etm.2020.9344.","journal-title":"Exp Ther Med"},{"key":"4499_CR16","doi-asserted-by":"publisher","first-page":"28903","DOI":"10.18632\/oncotarget.25627","volume":"9","author":"MC Kirchberger","year":"2018","unstructured":"Kirchberger MC, Moreira A, Erdmann M, Schuler G, Heinzerling L. Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients. Oncotarget. 2018;9:28903\u20139. https:\/\/doi.org\/10.18632\/oncotarget.25627.","journal-title":"Oncotarget"},{"key":"4499_CR17","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2021.5190","author":"M Fallico","year":"2021","unstructured":"Fallico M, Raciti G, Longo A, Reibaldi M, Bonfiglio V, Russo A, et al. Current molecular and clinical insights into uveal melanoma (review). Int J Oncol. 2021. https:\/\/doi.org\/10.3892\/ijo.2021.5190.","journal-title":"Int J Oncol"},{"key":"4499_CR18","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1158\/1541-7786.mcr-18-0574","volume":"17","author":"D Lapadula","year":"2019","unstructured":"Lapadula D, Farias E, Randolph CE, Purwin TJ, McGrath D, Charpentier TH, et al. Effects of oncogenic G\u03b1q and G\u03b111 inhibition by FR900359 in uveal melanoma. Mol Cancer Res. 2019;17:963\u201373. https:\/\/doi.org\/10.1158\/1541-7786.mcr-18-0574.","journal-title":"Mol Cancer Res"},{"key":"4499_CR19","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/pcmr.13161","volume":"37","author":"X Liu","year":"2024","unstructured":"Liu X, Run\u2010hua Z, Pan J, Li Z, Yu L, Li Y. Emerging therapeutic strategies for metastatic uveal melanoma: targeting driver mutations. Pigment Cell Melanoma Res. 2024;37:411\u201325. https:\/\/doi.org\/10.1111\/pcmr.13161.","journal-title":"Pigment Cell Melanoma Res"},{"key":"4499_CR20","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1056\/nejmoa2304753","volume":"389","author":"JC Hassel","year":"2023","unstructured":"Hassel JC, Piperno-Neumann S, Rutkowski P, Baurain JF, Schlaak M, Butler MO, et al. Three-year overall survival with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2023;389:2256\u201366. https:\/\/doi.org\/10.1056\/nejmoa2304753.","journal-title":"N Engl J Med"},{"key":"4499_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133066","volume":"14","author":"P Silva-Rodr\u00edguez","year":"2022","unstructured":"Silva-Rodr\u00edguez P, Fern\u00e1ndez-D\u00edaz D, Bande M, Pardo M, Loidi L, Blanco-Teijeiro MJ. GNAQ and GNA11 genes: a comprehensive review on oncogenesis, prognosis and therapeutic opportunities in uveal melanoma. Cancers Basel. 2022;14:3066. https:\/\/doi.org\/10.3390\/cancers14133066.","journal-title":"Cancers Basel"},{"key":"4499_CR22","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/s41588-019-0440-9","volume":"51","author":"AH Shain","year":"2019","unstructured":"Shain AH, Bagger MM, Yu R, Chang D, Liu S, Vemula S, et al. The genetic evolution of metastatic uveal melanoma. Nat Genet. 2019;51:1123\u201330. https:\/\/doi.org\/10.1038\/s41588-019-0440-9.","journal-title":"Nat Genet"},{"key":"4499_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/cmr.0000000000001089","volume":"36","author":"K Yang","year":"2026","unstructured":"Yang K, Wu D. Recent advances in the molecular genetic mechanisms and immune microenvironment of uveal melanoma. Melanoma Res. 2026;36:145\u201357. https:\/\/doi.org\/10.1097\/cmr.0000000000001089.","journal-title":"Melanoma Res"},{"key":"4499_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194927","volume":"14","author":"D Cilloni","year":"2022","unstructured":"Cilloni D, Itri F, Bonuomo V, Petiti J. SF3B1 mutations in hematological malignancies. Cancers (Basel). 2022;14:4927. https:\/\/doi.org\/10.3390\/cancers14194927.","journal-title":"Cancers (Basel)"},{"key":"4499_CR25","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1158\/1078-0432.ccr-15-2071","volume":"22","author":"MG Field","year":"2016","unstructured":"Field MG, Decatur CL, Kurtenbach S, Gezgin G, van der Velden PA, Jager MJ, et al. PRAME as an independent biomarker for metastasis in uveal melanoma. Clin Cancer Res. 2016;22:1234\u201342. https:\/\/doi.org\/10.1158\/1078-0432.ccr-15-2071.","journal-title":"Clin Cancer Res"},{"key":"4499_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081200","volume":"11","author":"NM van Poppelen","year":"2019","unstructured":"van Poppelen NM, Drabarek W, Smit KN, Vaarwater J, Brands T, Paridaens D, et al. SRSF2 mutations in uveal melanoma: a preference for in-frame deletions? Cancers Basel. 2019;11:1200. https:\/\/doi.org\/10.3390\/cancers11081200.","journal-title":"Cancers Basel"},{"key":"4499_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cells13121023","volume":"13","author":"A Fuentes-Rodriguez","year":"2024","unstructured":"Fuentes-Rodriguez A, Mitchell A, Gu\u00e9rin SL, Landreville S. Recent advances in molecular and genetic research on uveal melanoma. Cells. 2024;13:1023. https:\/\/doi.org\/10.3390\/cells13121023.","journal-title":"Cells"},{"key":"4499_CR28","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/ng.3549","volume":"48","author":"AR Moore","year":"2016","unstructured":"Moore AR, Ceraudo E, Sher JJ, Guan Y, Shoushtari AN, Chang MT, et al. Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nat Genet. 2016;48:675\u201380. https:\/\/doi.org\/10.1038\/ng.3549.","journal-title":"Nat Genet"},{"key":"4499_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-07865-x","author":"RJ Nell","year":"2021","unstructured":"Nell RJ, Menger NV, Versluis M, Luyten GPM, Verdijk RM, Madigan MC, et al. Involvement of mutant and wild-type CYSLTR2 in the development and progression of uveal nevi and melanoma. BMC Cancer. 2021. https:\/\/doi.org\/10.1186\/s12885-021-07865-x.","journal-title":"BMC Cancer"},{"key":"4499_CR30","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrg816","volume":"3","author":"PA Jones","year":"2002","unstructured":"Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415\u201328. https:\/\/doi.org\/10.1038\/nrg816.","journal-title":"Nat Rev Genet"},{"key":"4499_CR31","doi-asserted-by":"publisher","first-page":"59209","DOI":"10.18632\/oncotarget.10962","volume":"7","author":"MG Field","year":"2016","unstructured":"Field MG, Durante MA, Decatur CL, Tarlan B, Oelschlager KM, Stone JF, et al. Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in class 1 and class 2 uveal melanomas. Oncotarget. 2016;7:59209\u201319. https:\/\/doi.org\/10.18632\/oncotarget.10962.","journal-title":"Oncotarget"},{"key":"4499_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155314","volume":"21","author":"P Chokhachi Baradaran","year":"2020","unstructured":"Chokhachi Baradaran P, Kozovska Z, Furdova A, Smolkova B. Targeting epigenetic modifications in uveal melanoma. Int J Mol Sci. 2020;21:5314. https:\/\/doi.org\/10.3390\/ijms21155314.","journal-title":"Int J Mol Sci"},{"key":"4499_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-03964-8","author":"KN Smit","year":"2022","unstructured":"Smit KN, Boers R, Vaarwater J, Boers J, Brands T, Mensink H, et al. Genome-wide aberrant methylation in primary metastatic UM and their matched metastases. Sci Rep. 2022. https:\/\/doi.org\/10.1038\/s41598-021-03964-8.","journal-title":"Sci Rep"},{"key":"4499_CR34","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/1078-0432.ccr-11-0946","volume":"18","author":"S Landreville","year":"2012","unstructured":"Landreville S, Agapova OA, Matatall KA, Kneass ZT, Onken MD, Lee RS, et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res. 2012;18:408\u201316. https:\/\/doi.org\/10.1158\/1078-0432.ccr-11-0946.","journal-title":"Clin Cancer Res"},{"key":"4499_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax1738","author":"JN Kuznetsov","year":"2019","unstructured":"Kuznetsov JN, Aguero TH, Owens DA, Kurtenbach S, Field MG, Durante MA, et al. BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers. Sci Adv. 2019. https:\/\/doi.org\/10.1126\/sciadv.aax1738.","journal-title":"Sci Adv"},{"key":"4499_CR36","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41576-023-00662-1","volume":"25","author":"K Nemeth","year":"2023","unstructured":"Nemeth K, Bayraktar R, Ferracin M, Calin GA. Non-coding RNAs in disease: from mechanisms to therapeutics. Nat Rev Genet. 2023;25:211\u201332. https:\/\/doi.org\/10.1038\/s41576-023-00662-1.","journal-title":"Nat Rev Genet"},{"key":"4499_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13235919","volume":"13","author":"C Barbagallo","year":"2021","unstructured":"Barbagallo C, Platania CBM, Drago F, Barbagallo D, Di Pietro C, Purrello M, et al. Do extracellular RNAs provide insight into uveal melanoma biology? Cancers. 2021;13:5919. https:\/\/doi.org\/10.3390\/cancers13235919.","journal-title":"Cancers"},{"key":"4499_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030775","volume":"15","author":"C Barbagallo","year":"2023","unstructured":"Barbagallo C, Stella M, Broggi G, Russo A, Caltabiano R, Ragusa M. Genetics and RNA regulation of uveal melanoma. Cancers. 2023;15:775. https:\/\/doi.org\/10.3390\/cancers15030775.","journal-title":"Cancers"},{"key":"4499_CR39","doi-asserted-by":"publisher","first-page":"6351","DOI":"10.2147\/ott.s253946","volume":"13","author":"YF Li","year":"2020","unstructured":"Li YF, Dong L, Li Y, Wei WB. A review of microRNA in uveal melanoma. OncoTargets Ther. 2020;13:6351\u20139. https:\/\/doi.org\/10.2147\/ott.s253946.","journal-title":"OncoTargets Ther"},{"key":"4499_CR40","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920965852","author":"Y Li","year":"2020","unstructured":"Li Y, Shi J, Yang J, Ge S, Zhang J, Jia R, et al. Uveal melanoma: progress in molecular biology and therapeutics. Ther Adv Med Oncol. 2020. https:\/\/doi.org\/10.1177\/1758835920965852.","journal-title":"Ther Adv Med Oncol"},{"key":"4499_CR41","doi-asserted-by":"publisher","first-page":"0229","DOI":"10.1358\/dof.2011.36.3.1583187","volume":"36","author":"JA Gollob","year":"2011","unstructured":"Gollob JA, Bumcrot D, Toudjarska I, Bastian BC, Sah DW, Vaishnav AK. Progress in the delivery of siRNA therapeutics: potential in uveal melanoma. Drugs Future. 2011;36:0229. https:\/\/doi.org\/10.1358\/dof.2011.36.3.1583187.","journal-title":"Drugs Future"},{"key":"4499_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.70425","author":"A Azani","year":"2025","unstructured":"Azani A, Ghassemifar V, Mehrdad Z, Saberivand M, Bagheripour A, Tahmasebi S, et al. Toward precision medicine: gene therapy applications in the management of uveal melanoma. Cancer Rep. 2025. https:\/\/doi.org\/10.1002\/cnr2.70425.","journal-title":"Cancer Rep"},{"key":"4499_CR43","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3892\/or.2015.3949","volume":"34","author":"H Liu","year":"2015","unstructured":"Liu H, Lei C, Long K, Yang X, Zhu Z, Zhang L, et al. Mutant GNAQ promotes cell viability and migration of uveal melanoma cells through the activation of Notch signaling. Oncol Rep. 2015;34:295\u2013301. https:\/\/doi.org\/10.3892\/or.2015.3949.","journal-title":"Oncol Rep"},{"key":"4499_CR44","doi-asserted-by":"publisher","first-page":"5766","DOI":"10.1002\/jcb.27863","volume":"120","author":"Y Li","year":"2018","unstructured":"Li Y, He J, Qiu C, Shang Q, Qian G, Fan X, et al. The oncolytic virus H101 combined with GNAQ siRNA\u2010mediated knockdown reduces uveal melanoma cell viability. J Cell Biochem. 2018;120:5766\u201376. https:\/\/doi.org\/10.1002\/jcb.27863.","journal-title":"J Cell Biochem"},{"key":"4499_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133451","volume":"15","author":"A Han","year":"2023","unstructured":"Han A, Mukha D, Chua V, Purwin TJ, Tiago M, Modasia B, et al. Co-targeting FASN and mTOR suppresses uveal melanoma growth. Cancers. 2023;15:3451. https:\/\/doi.org\/10.3390\/cancers15133451.","journal-title":"Cancers"},{"key":"4499_CR46","doi-asserted-by":"publisher","first-page":"5522","DOI":"10.1167\/iovs.09-3804","volume":"50","author":"H Li","year":"2009","unstructured":"Li H, Yang W, Chen PW, Alizadeh H, Niederkorn JY. Inhibition of chemokine receptor expression on uveal melanomas by CXCR4 siRNA and its effect on uveal melanoma liver metastases. Invest Ophthalmol Vis Sci. 2009;50:5522. https:\/\/doi.org\/10.1167\/iovs.09-3804.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4499_CR47","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.2147\/ott.s136785","volume":"10","author":"H Liu","year":"2017","unstructured":"Liu H, Zhou M. Evaluation of p53 gene expression and prognosis characteristics in uveal melanoma cases. OncoTargets Ther. 2017;10:3429\u201334. https:\/\/doi.org\/10.2147\/ott.s136785.","journal-title":"OncoTargets Ther"},{"key":"4499_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044301","volume":"7","author":"X Huang","year":"2012","unstructured":"Huang X, Wang L, Zhang H, Wang H, Zhao X, Qian G, et al. Therapeutic efficacy by targeting correction of Notch1-induced aberrants in uveal tumors. PLoS ONE. 2012;7:e44301. https:\/\/doi.org\/10.1371\/journal.pone.0044301.","journal-title":"PLoS ONE"},{"key":"4499_CR49","doi-asserted-by":"publisher","first-page":"544","DOI":"10.4161\/cbt.28157","volume":"15","author":"F Duan","year":"2014","unstructured":"Duan F, Lin M, Li C, Ding X, Qian G, Zhang H, et al. Effects of inhibition of hedgehog signaling on cell growth and migration of uveal melanoma cells. Cancer Biol Ther. 2014;15:544\u201359. https:\/\/doi.org\/10.4161\/cbt.28157.","journal-title":"Cancer Biol Ther"},{"key":"4499_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18010226","volume":"18","author":"L Lu","year":"2017","unstructured":"Lu L, Yu X, Zhang L, Ding X, Pan H, Wen X, et al. The long non-coding RNA RHPN1-AS1 promotes uveal melanoma progression. Int J Mol Sci. 2017;18:226. https:\/\/doi.org\/10.3390\/ijms18010226.","journal-title":"Int J Mol Sci"},{"key":"4499_CR51","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.26355\/eurrev_201904_17566","volume":"23","author":"XM Huang","year":"2019","unstructured":"Huang XM, Shi SS, Jian TM, Tang DR, Wu T, Sun FY. LncRNA PVT1 knockdown affects proliferation and apoptosis of uveal melanoma cells by inhibiting EZH2. Eur Rev Med Pharmacol Sci. 2019;23:2880\u20137. https:\/\/doi.org\/10.26355\/eurrev_201904_17566.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"4499_CR52","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.2147\/ott.s203888","volume":"12","author":"H Zhao","year":"2019","unstructured":"Zhao H, Pan H, Wang H, Chai P, Ge S, Jia R, et al. SKP2 targeted inhibition suppresses human uveal melanoma progression by blocking ubiquitylation of p27. Onco Targets Ther. 2019;12:4297\u2013308. https:\/\/doi.org\/10.2147\/ott.s203888.","journal-title":"Onco Targets Ther"},{"key":"4499_CR53","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.64.4.23","volume":"64","author":"H Wang","year":"2023","unstructured":"Wang H, Pan H, Huang X. AURKB enhances chromosomal remodeling of telomeric genes and accelerates tumorigenesis of uveal melanoma. Invest Ophthalmol Vis Sci. 2023;64:23. https:\/\/doi.org\/10.1167\/iovs.64.4.23.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4499_CR54","doi-asserted-by":"publisher","DOI":"10.1007\/s10544-014-9908-7","author":"C Posch","year":"2015","unstructured":"Posch C, Latorre A, Crosby MB, Celli A, Latorre A, Vujic I, et al. Detection of GNAQ mutations and reduction of cell viability in uveal melanoma cells with functionalized gold nanoparticles. Biomed Microdevices. 2015. https:\/\/doi.org\/10.1007\/s10544-014-9908-7.","journal-title":"Biomed Microdevices"},{"key":"4499_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.118894","volume":"573","author":"L Xie","year":"2020","unstructured":"Xie L, Yang Y, Shen J. Efficient inhibition of uveal melanoma via ternary siRNA complexes. Int J Pharm. 2020;573:118894. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.118894.","journal-title":"Int J Pharm"},{"key":"4499_CR56","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1167\/iovs.08-2681","volume":"50","author":"D Yan","year":"2009","unstructured":"Yan D, Zhou X, Chen X, Hu DN, Dong XD, Wang J, et al. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. Invest Ophthalmol Vis Sci. 2009;50:1559. https:\/\/doi.org\/10.1167\/iovs.08-2681.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4499_CR57","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1167\/iovs.10-5272","volume":"52","author":"X Chen","year":"2011","unstructured":"Chen X, Wang J, Shen H, Lu J, Li C, Hu DN, et al. Epigenetics, microRNAs, and carcinogenesis: functional role of microRNA-137 in uveal melanoma. Invest Ophthalmol Vis Sci. 2011;52:1193. https:\/\/doi.org\/10.1167\/iovs.10-5272.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4499_CR58","first-page":"537","volume":"18","author":"F Dong","year":"2012","unstructured":"Dong F, Lou D. MicroRNA-34b\/c suppresses uveal melanoma cell proliferation and migration through multiple targets. Mol Vis. 2012;18:537\u201346.","journal-title":"Mol Vis"},{"key":"4499_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061468","volume":"12","author":"A Amaro","year":"2020","unstructured":"Amaro A, Croce M, Ferrini S, Barisione G, Gualco M, Perri P, et al. Potential onco-suppressive role of miR122 and miR144 in uveal melanoma through ADAM10 and C-met inhibition. Cancers (Basel). 2020;12:1468. https:\/\/doi.org\/10.3390\/cancers12061468.","journal-title":"Cancers (Basel)"},{"key":"4499_CR60","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3892\/or.2012.1905","volume":"28","author":"N Liu","year":"2012","unstructured":"Liu N, Sun Q, Chen J, Li J, Zeng Y, Zhai S, et al. MicroRNA-9 suppresses uveal melanoma cell migration and invasion through the NF-\u03baB1 pathway. Oncol Rep. 2012;28:961\u20138. https:\/\/doi.org\/10.3892\/or.2012.1905.","journal-title":"Oncol Rep"},{"key":"4499_CR61","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.molonc.2013.08.003","volume":"7","author":"J Liu","year":"2013","unstructured":"Liu J, Ma L, Li C, Zhang Z, Yang G, Zhang W. Tumor\u2010targeting TRAIL expression mediated by miRNA response elements suppressed growth of uveal melanoma cells. Mol Oncol. 2013;7:1043\u201355. https:\/\/doi.org\/10.1016\/j.molonc.2013.08.003.","journal-title":"Mol Oncol"},{"key":"4499_CR62","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.3760\/cma.j.issn.0366-6999.20133206","volume":"127","author":"L Yang","year":"2014","unstructured":"Yang L, Qiming H, Xuehui S, Xiang J, Li S, Xiaolin X, et al. MicroRNA 145 may play an important role in uveal melanoma cell growth by potentially targeting insulin receptor substrate-1. Chin Med J. 2014;127:1410\u20136. https:\/\/doi.org\/10.3760\/cma.j.issn.0366-6999.20133206.","journal-title":"Chin Med J"},{"key":"4499_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040967","volume":"7","author":"D Yan","year":"2012","unstructured":"Yan D, Dong XD, Chen X, Yao S, Wang L, Wang J, et al. Role of microRNA-182 in posterior uveal melanoma: regulation of tumor development through MITF, BCL2 and cyclin D2. PLoS ONE. 2012;7:e40967. https:\/\/doi.org\/10.1371\/journal.pone.0040967.","journal-title":"PLoS ONE"},{"key":"4499_CR64","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1167\/iovs.12-10977","volume":"54","author":"X Chen","year":"2013","unstructured":"Chen X, He D, Dong XD, Dong F, Wang J, Wang L, et al. MicroRNA-124a is epigenetically regulated and acts as a tumor suppressor by controlling multiple targets in uveal melanoma. Invest Ophthalmol Vis Sci. 2013;54:2248. https:\/\/doi.org\/10.1167\/iovs.12-10977.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4499_CR65","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/cmr.0000000000000140","volume":"25","author":"Y Zhou","year":"2015","unstructured":"Zhou Y, Zhang L, Fan J, Jia R, Song X, Xu X, et al. Let-7b overexpression leads to increased radiosensitivity of uveal melanoma cells. Melanoma Res. 2015;25:119\u201326. https:\/\/doi.org\/10.1097\/cmr.0000000000000140.","journal-title":"Melanoma Res"},{"key":"4499_CR66","doi-asserted-by":"publisher","first-page":"4729","DOI":"10.2147\/cmar.s206461","volume":"11","author":"D Peng","year":"2019","unstructured":"Peng D, Dong J, Zhao Y, Peng X, Tang J, Chen X, et al. MiR-142-3p suppresses uveal melanoma by targeting CDC25C, TGF\u03b2R1, GNAQ, WASL, and RAC1. Cancer Manag Res. 2019;11:4729\u201342. https:\/\/doi.org\/10.2147\/cmar.s206461.","journal-title":"Cancer Manag Res"},{"key":"4499_CR67","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/cm9.0000000000000875","volume":"133","author":"JY Yang","year":"2020","unstructured":"Yang JY, Li Y, Wang Q, Zhou WJ, Yan YN, Wei WB. MicroRNA-145 suppresses uveal melanoma angiogenesis and growth by targeting neuroblastoma RAS viral oncogene homolog and vascular endothelial growth factor. Chin Med J. 2020;133:1922\u20139. https:\/\/doi.org\/10.1097\/cm9.0000000000000875.","journal-title":"Chin Med J"},{"key":"4499_CR68","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11010-017-3248-x","volume":"445","author":"X Wang","year":"2017","unstructured":"Wang X, Hu Y, Cui J, Zhou Y, Chen L. Coordinated targeting of MMP-2\/MMP-9 by miR-296-3p\/FOXCUT exerts tumor-suppressing effects in choroidal malignant melanoma. Mol Cell Biochem. 2017;445:25\u201333. https:\/\/doi.org\/10.1007\/s11010-017-3248-x.","journal-title":"Mol Cell Biochem"},{"key":"4499_CR69","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.bbrc.2018.05.069","volume":"501","author":"Y Liu","year":"2018","unstructured":"Liu Y, Huo Y, Wang D, Tai Y, Li J, Pang D, et al. MiR-216a-5p\/Hexokinase 2 axis regulates uveal melanoma growth through modulation of Warburg effect. Biochem Biophys Res Commun. 2018;501:885\u201392. https:\/\/doi.org\/10.1016\/j.bbrc.2018.05.069.","journal-title":"Biochem Biophys Res Commun"},{"key":"4499_CR70","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.1167\/iovs.19-27704","volume":"60","author":"S Wu","year":"2019","unstructured":"Wu S, Chen H, Han N, Zhang C, Yan H. Long noncoding RNA PVT1 silencing prevents the development of uveal melanoma by impairing microRNA-17-3p\u2013dependent MDM2 upregulation. Invest Ophthalmol Vis Sci. 2019;60:4904. https:\/\/doi.org\/10.1167\/iovs.19-27704.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4499_CR71","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1167\/iovs.18-26477","volume":"60","author":"Q Hou","year":"2019","unstructured":"Hou Q, Han S, Yang L, Chen S, Chen J, Ma N, et al. The interplay of microRNA-34a, LGR4, EMT-associated factors, and MMP2 in regulating uveal melanoma cells. Invest Ophthalmol Vis Sci. 2019;60:4503. https:\/\/doi.org\/10.1167\/iovs.18-26477.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4499_CR72","doi-asserted-by":"publisher","first-page":"718","DOI":"10.18240\/ijo.2020.05.04","volume":"13","author":"Y Li","year":"2020","unstructured":"Li Y. MiRNA-145\/miRNA-205 inhibits proliferation and invasion of uveal melanoma cells by targeting NPR1\/CDC42. Int J Ophthalmol. 2020;13:718\u201324. https:\/\/doi.org\/10.18240\/ijo.2020.05.04.","journal-title":"Int J Ophthalmol"},{"key":"4499_CR73","doi-asserted-by":"publisher","first-page":"12412","DOI":"10.1002\/jcb.28507","volume":"120","author":"J Li","year":"2019","unstructured":"Li J, Liu X, Li C, Wang W. MiR\u2010224\u20105p inhibits proliferation, migration, and invasion by targeting PIK3R3\/AKT3 in uveal melanoma. J Cell Biochem. 2019;120:12412\u201321. https:\/\/doi.org\/10.1002\/jcb.28507.","journal-title":"J Cell Biochem"},{"key":"4499_CR74","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nrc2695","volume":"9","author":"J Xu","year":"2009","unstructured":"Xu J, Wu R-C, O\u2019Malley BW. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer. 2009;9:615\u201330. https:\/\/doi.org\/10.1038\/nrc2695.","journal-title":"Nat Rev Cancer"},{"key":"4499_CR75","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1210\/me.2015-1080","volume":"29","author":"VK Eedunuri","year":"2015","unstructured":"Eedunuri VK, Rajapakshe K, Fiskus W, Geng C, Chew SA, Foley C, et al. MiR-137 targets p160 steroid receptor coactivators SRC1, SRC2, and SRC3 and inhibits cell proliferation. Mol Endocrinol. 2015;29:1170\u201383. https:\/\/doi.org\/10.1210\/me.2015-1080.","journal-title":"Mol Endocrinol"},{"key":"4499_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-015-0156-3","author":"I Venza","year":"2015","unstructured":"Venza I, Visalli M, Beninati C, Benfatto S, Teti D, Venza M. IL-10R\u03b1 expression is post-transcriptionally regulated by miR-15a, miR-185, and miR-211 in melanoma. BMC Med Genomics. 2015. https:\/\/doi.org\/10.1186\/s12920-015-0156-3.","journal-title":"BMC Med Genomics"},{"key":"4499_CR77","first-page":"3939","volume":"8","author":"L Sun","year":"2016","unstructured":"Sun L, Sun P, Zhou QY, Gao X, Han Q. Long noncoding RNA MALAT1 promotes uveal melanoma cell growth and invasion by silencing of miR-140. Am J Transl Res. 2016;8:3939\u201346.\u00a0https:\/\/e-century.us\/files\/ajtr\/8\/9\/ajtr0024434.pdf.","journal-title":"Am J Transl Res"},{"key":"4499_CR78","doi-asserted-by":"publisher","first-page":"14756","DOI":"10.1021\/acsnano.4c16427","volume":"19","author":"Z Jiang","year":"2025","unstructured":"Jiang Z, Yang Y, Yue Z, Chen Y, Bai L, Wang R, et al. A noninvasive nanoeyedrop therapy for the inhibition of uveal melanoma: tetrahedral framework nucleic acid\u2013based bioswitchable microRNA delivery system. ACS Nano. 2025;19:14756\u201369. https:\/\/doi.org\/10.1021\/acsnano.4c16427.","journal-title":"ACS Nano"},{"key":"4499_CR79","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1007\/s13346-025-01849-1","volume":"16","author":"S Barrios-Esteban","year":"2025","unstructured":"Barrios-Esteban S, Alcalde I, Chac\u00f3n M, Merayo-Lloves J, de la Fuente M, Csaba N. Protamine nanocapsules as gene delivery carriers for the treatment of intraocular tumors. Drug Deliv Transl Res. 2025;16:1754\u201372. https:\/\/doi.org\/10.1007\/s13346-025-01849-1.","journal-title":"Drug Deliv Transl Res"},{"key":"4499_CR80","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ncrna.2025.01.004","volume":"11","author":"B Chodurska","year":"2025","unstructured":"Chodurska B, Kunej T. Long non-coding RNAs in humans: classification, genomic organization and function. Non-coding RNA Res. 2025;11:313\u201327. https:\/\/doi.org\/10.1016\/j.ncrna.2025.01.004.","journal-title":"Non-coding RNA Res"},{"key":"4499_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164041","volume":"13","author":"P Mil\u00e1n-Rois","year":"2021","unstructured":"Mil\u00e1n-Rois P, Quan A, Slack FJ, Somoza \u00c1. The role of lncRNAs in uveal melanoma. Cancers (Basel). 2021;13:4041. https:\/\/doi.org\/10.3390\/cancers13164041.","journal-title":"Cancers (Basel)"},{"key":"4499_CR82","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1002\/1873-3468.12220","volume":"590","author":"X Ding","year":"2016","unstructured":"Ding X, Wang X, Lin M, Xing Y, Ge S, Jia R, et al. PAUPAR lncRNA suppresses tumourigenesis by H3K4 demethylation in uveal melanoma. FEBS Lett. 2016;590:1729\u201338. https:\/\/doi.org\/10.1002\/1873-3468.12220.","journal-title":"FEBS Lett"},{"key":"4499_CR83","doi-asserted-by":"publisher","first-page":"12779","DOI":"10.1007\/s13277-016-5243-3","volume":"37","author":"G Cheng","year":"2016","unstructured":"Cheng G, He J, Zhang L, Ge S, Zhang H, Fan X. HIC1 modulates uveal melanoma progression by activating lncRNA-numb. Tumor Biol. 2016;37:12779\u201389. https:\/\/doi.org\/10.1007\/s13277-016-5243-3.","journal-title":"Tumor Biol"},{"key":"4499_CR84","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.ymthe.2017.02.016","volume":"25","author":"Y Xing","year":"2017","unstructured":"Xing Y, Wen X, Ding X, Fan J, Chai P, Jia R, et al. CANT1 lncRNA triggers efficient therapeutic efficacy by correcting aberrant Incing cascade in malignant uveal melanoma. Mol Ther. 2017;25:1209\u201321. https:\/\/doi.org\/10.1016\/j.ymthe.2017.02.016.","journal-title":"Mol Ther"},{"key":"4499_CR85","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1080\/15548627.2019.1659614","volume":"16","author":"P Li","year":"2019","unstructured":"Li P, He J, Yang Z, Ge S, Zhang H, Zhong Q, et al. ZNNT1 long noncoding RNA induces autophagy to inhibit tumorigenesis of uveal melanoma by regulating key autophagy gene expression. Autophagy. 2019;16:1186\u201399. https:\/\/doi.org\/10.1080\/15548627.2019.1659614.","journal-title":"Autophagy"},{"key":"4499_CR86","doi-asserted-by":"publisher","first-page":"12259","DOI":"10.2147\/cmar.s260866","volume":"12","author":"Y Qi","year":"2020","unstructured":"Qi Y, Cui Q, Zhang W, Yao R, Xu D, Zhang F. Long non-coding RNA GAS5 targeting microRNA-21 to suppress the invasion and epithelial\u2013mesenchymal transition of uveal melanoma. Cancer Manag Res. 2020;12:12259\u201367. https:\/\/doi.org\/10.2147\/cmar.s260866.","journal-title":"Cancer Manag Res"},{"key":"4499_CR87","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.11240","author":"X Wu","year":"2019","unstructured":"Wu X, Yuan Y, Ma R, Xu B, Zhang R. LncRNA SNHG7 affects malignant tumor behaviors through downregulation of EZH2 in uveal melanoma cell lines. Oncol Lett. 2019. https:\/\/doi.org\/10.3892\/ol.2019.11240.","journal-title":"Oncol Lett"},{"key":"4499_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133186","volume":"14","author":"K Glinkina","year":"2022","unstructured":"Glinkina K, Groenewoud A, Teunisse AFAS, Snaar-Jagalska BE, Jochemsen AG. Novel treatments of uveal melanoma identified with a synthetic lethal CRISPR\/Cas9 screen. Cancers (Basel). 2022;14:3186. https:\/\/doi.org\/10.3390\/cancers14133186.","journal-title":"Cancers (Basel)"},{"key":"4499_CR89","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1038\/s41588-025-02222-1","volume":"57","author":"PY Chan","year":"2025","unstructured":"Chan PY, Alexander D, Mehta I, Matsuyama LSAS, Harle V, Olvera-Le\u00f3n R, et al. The synthetic lethal interaction between CDS1 and CDS2 is a vulnerability in uveal melanoma and across multiple tumor types. Nat Genet. 2025;57:1672\u201383. https:\/\/doi.org\/10.1038\/s41588-025-02222-1.","journal-title":"Nat Genet"},{"key":"4499_CR90","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.exer.2018.04.009","volume":"172","author":"S Liu","year":"2018","unstructured":"Liu S, Song W, Liu F, Zhang J, Zhu S. Antitumor efficacy of VP22-CD\/5-FC suicide gene system mediated by lentivirus in a murine uveal melanoma model. Exp Eye Res. 2018;172:144\u201351. https:\/\/doi.org\/10.1016\/j.exer.2018.04.009.","journal-title":"Exp Eye Res"},{"key":"4499_CR91","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1159\/000508383","volume":"6","author":"TA Sussman","year":"2020","unstructured":"Sussman TA, Funchain P, Singh A. Clinical trials in metastatic uveal melanoma: current status. Ocul Oncol Pathol. 2020;6:381\u20137. https:\/\/doi.org\/10.1159\/000508383.","journal-title":"Ocul Oncol Pathol"},{"key":"4499_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.785231","author":"EAT Koch","year":"2022","unstructured":"Koch EAT, Schaft N, Kummer M, Berking C, Schuler G, Hasumi K, et al. A one-armed Phase I dose escalation trial design: personalized vaccination with IKK\u03b2-matured, RNA-loaded dendritic cells for metastatic uveal melanoma. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.785231.","journal-title":"Front Immunol"},{"key":"4499_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100089","volume":"15","author":"MW Rohaan","year":"2022","unstructured":"Rohaan MW, Gomez-Eerland R, van den Berg JH, Geukes Foppen MH, van Zon M, Raud B, et al. MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I\/IIa clinical trial. Immuno-Oncol Technol. 2022;15:100089. https:\/\/doi.org\/10.1016\/j.iotech.2022.100089.","journal-title":"Immuno-Oncol Technol"},{"key":"4499_CR94","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1080\/13816810.2021.1961280","volume":"42","author":"DF Akin-Bali","year":"2021","unstructured":"Akin-Bali DF. Bioinformatics analysis of GNAQ, GNA11, BAP1, SF3B1, SRSF2, EIF1AX, PLCB4, and CYSLTR2 genes and their role in the pathogenesis of uveal melanoma. Ophthalmic Genet. 2021;42:732\u201343. https:\/\/doi.org\/10.1080\/13816810.2021.1961280.","journal-title":"Ophthalmic Genet"},{"key":"4499_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060846","volume":"11","author":"M Croce","year":"2019","unstructured":"Croce M, Ferrini S, Pfeffer U, Gangemi R. Targeted therapy of uveal melanoma: recent failures and new perspectives. Cancers. 2019;11:846. https:\/\/doi.org\/10.3390\/cancers11060846.","journal-title":"Cancers"},{"key":"4499_CR96","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00018-020-03612-w","volume":"78","author":"C Yang","year":"2020","unstructured":"Yang C, Wang Y, Hardy P. Emerging roles of microRNAs and their implications in uveal melanoma. Cell Mol Life Sci. 2020;78:545\u201359. https:\/\/doi.org\/10.1007\/s00018-020-03612-w.","journal-title":"Cell Mol Life Sci"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04499-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04499-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04499-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T20:02:15Z","timestamp":1784059335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04499-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":96,"alternative-id":["4499"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04499-y","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No research involving humans or animals were perfomred as a part of this literature review.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this type of study, formal consent is not required.","order":3,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There is no conflict of Interest.","order":4,"name":"Ethics","label":"competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}